New CAR-T therapy targets tough leukemia in early trial

NCT ID NCT07198867

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 19 times

Summary

This early-phase study tests a new treatment called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) to attack the cancer. The main goals are to check safety and see if the therapy can shrink or eliminate the leukemia. About 20 adults aged 18 to 75 with adequate organ function can join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.